ArticleJournal of neuro-oncology2026
Neurocognitive functioning, seizure control, and return to work after awake surgery with or without adjuvant therapy in IDH-mutant grade 3 diffuse gliomas.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal oncological management of adult patients with IDH-mutant CNS WHO grade 3 diffuse gliomas remains debated, particularly given the potential neurotoxic effects of adjuvant therapies on cognition and health-related quality-of-life.
methodsWe conducted a retrospective single-center cohort study including 87 consecutive patients with IDH-mutant CNS WHO grade 3 glioma who underwent awake craniotomy. Patients were stratified into a surgery only group (n = 23) or an adjuvant oncological group (radiotherapy with or without chemotherapy; n = 64). Neurocognitive outcomes, seizure control, and return-to-work rates were assessed. Voxel-wise lesion-symptom mapping was performed to identify associations between radiation dose distribution and postoperative neurocognitive performance.
resultsPatients who did not receive postoperative adjuvant therapy showed better language (100% vs. 73.4%, p = 0.005) and executive and social function (95.6% vs. 70.1%, p = 0.013) outcomes. Left-sided tumor location and adjuvant treatment were independent predictors of poorer language and executive and social function outcomes, while adjuvant therapy was the only independent predictor of impaired executive and social function recovery. Voxel-wise lesion-symptom mapping analyses revealed significant associations between radiation exposure of specific white matter tracts involved in language and executive and social networks and postoperative neurocognitive decline. Seizure control did not differ between groups. Patients managed with surgery alone had higher 6-month employment rates and returned to work earlier.
conclusionIn this cohort, adjuvant therapy was associated with preliminary worse neurocognitive outcomes and reduced return-to-work rates, potentially reflecting the impact of radiation exposure on brain connectivity preserved during awake surgery. For selected patients, a watch-and-wait strategy following maximal safe resection may help preserve mid-term neurocognitive functioning.
Indexed as
Identifiers
41826771What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.